detalle del documento
IDENTIFICACIÓN
doi:10.1007/s00467-023-06240-1...
Autor
Yang, Yan Chen, Yan Yang, Yang Bai, Haitao He, Bizi Liu, DengliLangue
enEditor
Springer
Categoría
Urology
Año
2023
fecha de cotización
20/12/2023
Palabras clave
anemia roxadustat chronic kidney disease infant hypoxia-inducible factor prolyl hy... erythropoiesis-stimulating agent anemia childrenResumen
Background Erythropoiesis-stimulating agents (ESAs) have played an important role in the treatment of renal anemia in children, but cannot improve hemoglobin to target level in some cases.
Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, can stimulate endogenous erythropoietin production and regulate iron metabolism even in patients with kidney failure.
However, roxadustat has not yet been approved for use in children.
Case–diagnosis/Treatment We report a case of refractory renal anemia in an 80-day-old boy, who was hyporesponsive to ESAs even in combination with iron supplementation and transfusion.
Compassionate use of roxadustat successfully corrected the intractable anemia.
Hyperkalemia is a manageable adverse event of concern during follow-up.
Conclusion The successful experience in this case may inform the clinical utility of roxadustat for refractory renal anemia in children, which should be further confirmed by well-designed prospective clinical trials.
Yang, Yan,Chen, Yan,Yang, Yang,Bai, Haitao,He, Bizi,Liu, Dengli, 2023, Compassionate use of roxadustat for treatment of refractory renal anemia in an infant, Springer
Evaluating Image Hallucination in Text-to-Image Generation with Question-Answering
evaluation computer dataset images tti generation i-halla
Role of Repetitive Transcranial Magnetic Stimulation in Treatment of Fibromyalgia: A Randomized Controlled Trial
significant following stimulation fms treatment
